================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 15, 2003
BOSTON SCIENTIFIC CORPORATION
--------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
DELAWARE 1-11083 04-2695240
--------------- ----------- -------------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation)
ONE BOSTON SCIENTIFIC PLACE, NATICK, MASSACHUSETTS 01760-1537
-------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (508) 650-8000
================================================================================
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On September 15, 2003, Boston Scientific Corporation (the "Company")
issued a press release announcing nine-month results of its TAXUS IV clinical
trial. A copy of the release is attached to this report as exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibit.
99.1 Press Release issued by Boston Scientific Corporation
dated September 15, 2003.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
BOSTON SCIENTIFIC CORPORATION
Date: September 16, 2003 By: /s/ Lawrence J. Knopf
----------------------
Lawrence J. Knopf
Vice President and
Assistant General Counsel